Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America

Detalhes bibliográficos
Autor(a) principal: Arévalo-Herrera,Myriam
Data de Publicação: 2011
Outros Autores: Solarte,Yezid, Marin,Catherin, Santos,Mariana, Castellanos,Jenniffer, Beier,John C, Valencia,Sócrates Herrera
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900025
Resumo: Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
id FIOCRUZ-4_59d5af586e73885b32125bd6be85cb26
oai_identifier_str oai:scielo:S0074-02762011000900025
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin AmericamalariaPlasmodiumvaccinestransmission blocking immunitytransmission blocking vaccinevector-borne diseaseMalaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.Instituto Oswaldo Cruz, Ministério da Saúde2011-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900025Memórias do Instituto Oswaldo Cruz v.106 suppl.1 2011reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02762011000900025info:eu-repo/semantics/openAccessArévalo-Herrera,MyriamSolarte,YezidMarin,CatherinSantos,MarianaCastellanos,JennifferBeier,John CValencia,Sócrates Herreraeng2020-04-25T17:51:07Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:18:05.963Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
title Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
spellingShingle Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
Arévalo-Herrera,Myriam
malaria
Plasmodium
vaccines
transmission blocking immunity
transmission blocking vaccine
vector-borne disease
title_short Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
title_full Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
title_fullStr Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
title_full_unstemmed Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
title_sort Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
author Arévalo-Herrera,Myriam
author_facet Arévalo-Herrera,Myriam
Solarte,Yezid
Marin,Catherin
Santos,Mariana
Castellanos,Jenniffer
Beier,John C
Valencia,Sócrates Herrera
author_role author
author2 Solarte,Yezid
Marin,Catherin
Santos,Mariana
Castellanos,Jenniffer
Beier,John C
Valencia,Sócrates Herrera
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Arévalo-Herrera,Myriam
Solarte,Yezid
Marin,Catherin
Santos,Mariana
Castellanos,Jenniffer
Beier,John C
Valencia,Sócrates Herrera
dc.subject.por.fl_str_mv malaria
Plasmodium
vaccines
transmission blocking immunity
transmission blocking vaccine
vector-borne disease
topic malaria
Plasmodium
vaccines
transmission blocking immunity
transmission blocking vaccine
vector-borne disease
dc.description.none.fl_txt_mv Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
description Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
publishDate 2011
dc.date.none.fl_str_mv 2011-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900025
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000900025
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0074-02762011000900025
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.106 suppl.1 2011
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937711017885696